source
- As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune visionAbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster ca…BioSpace · 17h ago↗ source
- Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweepDisc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria w…BioSpace · 21h ago↗ source
- Moderna’s stock soars after Phase 3 success of melanoma vaccine with MerckBioPharma Dive’s latest data-visualization series charts Moderna’s dramatic stock rebound in 2026 after a period of decline. The company had struggled when demand for its COVID-19 vaccine fell, pr…